Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
|Articles|October 15, 2020

Bora Pharmaceuticals’ Bobby Sheng Wins ‘CEO of the Year’ at the CPhI Pharma Awards

The judges chose Sheng from a shortlist of seven candidates and highlighted his work in the Taiwanese and global markets while guiding the company through “pivotal changes” that demonstrated his abilities as a “top CEO.”

Bora Pharmaceuticals, a contract development and manufacturing organization, announced on Oct. 15, 2020 that its chairman and CEO, Bobby Sheng, was named ‘CEO of the Year’ at the CPhI Pharma Awards 2020.

The award is presented to a C-suite executive who demonstrates leadership skills to drive forward their organization, increase performance, and engage staff and customers, while remaining committed to the development of the pharma industry, a company press release said. The judges chose Sheng from a shortlist of seven candidates and highlighted his work in the Taiwanese and global markets while guiding the company through “pivotal changes” that demonstrated his abilities as a “top CEO.”

Throughout 2020, Sheng headed the expansion of Bora Pharmaceuticals from Asia into the United States and helped the company meet its international growth goals despite the ongoing COVID-19 pandemic, the press release said.

“Winning such a prestigious award is an incredible acknowledgement not just of me, but of the work, values, and expertise of the whole team at Bora Pharmaceuticals,” Sheng said in the press release. “I am incredibly proud of the growth we have achieved thanks to the excellent customer service, technical agility, and niche capabilities that the team at Bora provide to our customers across North America, Asia, and Europe.”

Source: Bora​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​


Related to this article

The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.